SEC Comment Letter 0000000000-24-009367 to MIRA PHARMACEUTICALS, INC. (MIRA) (CIK 0001904286) (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA) (CIK 0001904286)
Date: Aug. 15, 2024 · CIK: 0001904286 · Accession: 0000000000-24-009367
AI Filing Summary & Sentiment
File numbers found in text: 333-281467
Letter
August 15, 2024 Erez Aminov Chairman and Chief Executive Officer Mira Pharmaceuticals, Inc. 1200 Brickell Avenue, Suite 1950 #1183 Miami, Florida 33131 Re:Mira Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 12, 2024 File No. 333-281467 Dear Erez Aminov: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Max Lindenfeld
Show Raw Text
August 15, 2024
Erez Aminov
Chairman and Chief Executive Officer
Mira Pharmaceuticals, Inc.
1200 Brickell Avenue, Suite 1950 #1183
Miami, Florida 33131
Re:Mira Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 12, 2024
File No. 333-281467
Dear Erez Aminov:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Max Lindenfeld